Analysis of splenic ClpB was performed by quantitative PCR using 100 ng DNA as template
Dominique Fradin-Read is pleased to share the following: Treatments that have already been extensively tested in clinical trials and approved by the FDA Upcoming indications currently under research, showing highly promising preliminary results Neuroprotective Mechanisms We already have good clinical evidence supporting these neuroprotective effects: A large-scale study involving over 5 million obese adults found that GLP-1 receptor agonists were associated with a significantly lower risk of developing Alzheimer's, Lewy body dementia, and vascular dementia
Scully S, Evans AC, Carter F, Duffy P, Lonergan P, Crowe MA
Phase 3 TRIUMPH results are expected in 2026 and 2027, and Health Canada approval is likely in 2027 or 2028 if the late data holds up
Semaglutide does not require dose reduction based on kidney function because it is metabolized via amino acid pathways, not renal elimination
however, the mice in our study were E
.webp)
